Trial Profile
A PHASE II STUDY OF LENALIDOMIDE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OLDER THAN 65 YEARS OF AGE.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 25 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Nov 2015 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
- 24 Nov 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.